TP53 and acute myeloid leukemia: We recently reported that ATM/p53 overactivation is behind the synergy between M3814 and another DSB-inducing agent, calicheamicin, in the wild-type p53 AML cell line Molm-13 in vitro and in vivo, suggesting a new combination approach to improving AML treatment with Mylotarg26.